Reyes-Tobar P, Altamirano-Assad R, Osses-Donoso L, Nazzal-Nazal O, Suárez-Pacheco E

Language: English
References: 8
Page: 84-89
PDF size: 185.21 Kb.

ABSTRACT

Background: Small cell ovarian carcinoma of the hypercalcemic subtype (SCCOHT) is a rare and aggressive ovarian neoplasm that affects more frequently to young women, its landmark is the elevation of serum calcium and somatic mutations of the SMARC4 gen.
Clinical case: We present a case report of a 22 year old woman who attended to our emergency service due to a 48 hours long abdominal pain, at her arrival a transvaginal ultrasound was performed which showed a right adnexal, solid, 15 centimeters in size tumor, clinical examination was compatible with an acute abdomen. She underwent an emergency right salpingo oophorectomy because of the tumor was twisted, without other pathologic findings in the surgery. Serum markers where obtained, except for calcium, only lactate dehydrogenase was altered. The biopsy described a SCCOHT affecting the right ovary, because of these, a staging surgery (FIGO IIIC) follow by platinum-based chemotherapy and radiotherapy were performed, with good response from a clinical and imaging point of view. There are not been signs of recurrence up to her last appointment, in September 2019.
Conclusions: Regarding the treatment, there are no guidelines, but combine treatment: unconservative surgery along with chemotherapy and radiation seems to improve the outcome, despite this, the overall survival is low. Genetics techniques could play a key role in diagnosis and treatment.

REFERENCES

1. Brinda RK, Sanaz J, Silvana F, Tara S, Naveen G, Madhavi P, Srinivasa RP. Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Clinical and Imaging Review. Curr Probl Diag Radiol 2018; 47: 333-9. https://doi.org/10.1067/j. cpradiol.2017.08.004.

2. Bingjian L, Haiyan S. An in depth look at small cell carcinoma of the ovary, hypercalcemic type (SCOOHT): clinical implications from recent molecular findings. Journal of Cancer 2019; 10: 223-37. doi: 10.7150/jca.26978.

3. Young R, Oliva E, Scully R. Small cell carcinoma of the ovary, a clinicopathological analysis of 150 cases. Am J Surg Pathol 1994; 18: 1102-16. doi: 10.1097/00000478- 199411000-00004.

4. Callegaro-Filho D, Gershenson D, Nick A, Munsell M, Ramirez P, Eifel P, Euscher E et al. Small Cell Carcinoma of the Ovary-Hypercalcemic Type (SCCOHT): A Review of 47 Cases. Gynecol Oncol. 2016; 140: 53-57. https://doi. org/10.1016/j.ygyno.2015.11.004.

5. Tischkowitz M, Huang S, Banerjee S, Hague J, Hendricks W, Huntsman D, Lang J et al. Small-Cell Carcinoma of the Ovary, Hypercalcemic Type–Genetics, New Treatment Targets, and Current Management Guidelines. Clin Cancer Res 2020 Mar 10. doi: 10.1158/1078-0432.CCR-19-3797.

6. Lin D, Chudnovsky Y, Duggan B, Zajchowski D, Greenbowe J, Ross J, Gay L et al. Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type. Gynecol Oncol 2017; 147: 626-633. https://doi.org/10.1016/j.ygyno.2017.09.031.

7. Pautier P, Ribrag V, Duvillard P. Results of a prospective doseintensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type. Ann Oncol 2007; 18: 1985-9. https://doi.org/10.1093/annonc/mdm376.

8. Wang Y, Chen SY, Karnezis A, Colborne S, Dos Santos N, Lang J et al. Histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcemic type. J Pathol 2017; 242: 371-83. https://doi.org/10.1002/ path.4912.